NCT02754726 - Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

April 11, 2023

Study Completion Date

March 22, 2024

Conditions

Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

Nivolumab

Nivolumab 240mg 240 mg as a 60 minute infusion on days 1, 15, 29 per 42 day cycle

DRUG

Albumin-bound paclitaxel

125 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle

DRUG

Paricalcitol

25 micrograms IV on days 1,4,8,12,15,18,22,26,29,32,36,39 (+/-1 day allowed for dosing per 42 day cycle

DRUG

Cisplatin

25 mg/m2 over 60 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle

DRUG

Gemcitabine

1000 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle

Trial Locations (1)

Clinical Trials Nurse Navigator, Scottsdale